Robert M Baugh

US Patent:

6444228, Sep 3, 2002

Filed:

Apr 20, 1998

Appl. No.:

09/063338

Inventors:

Robert F. Baugh - Parker CO
Lisa M. Lim - Aurora CO
Julie S. Johnston - Highlands Ranch CO
John G. Rivera - Aurora CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

A61K 3516

US Classification:

424530, 424529, 424531, 424532

Abstract:

In general, the present invention relates to a two-phase method for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. First, a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma and platelet poor plasma are then divided into two portions. To the first portion, which is used in phase-one, a compound that reverses the effect of the anticoagulant is added, and a clot is allowed to form. The clot is then triturated and the resulting serum, containing autologous thrombin, is collected. The serum obtained from phase-one is then mixed with the second portion of the platelet rich plasma or platelet poor plasma, used in phase-two, to form the bioadhesive sealant of the present invention.

US Patent:

6468287, Oct 22, 2002

Filed:

Oct 29, 1998

Appl. No.:

09/308414

Inventors:

Robert F. Baugh - Parker CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

A61B 500

US Classification:

606181, 600583, 600576, 606266

Abstract:

A piercing instrument ( ) for obtaining a non-activated drop of blood (B) by capillary puncture is formed by depositing a coating agent ( ) on the exterior surface of the piercing instrument ( ). The coating agent comprises compounds that inhibit the activation of blood.

US Patent:

6472161, Oct 29, 2002

Filed:

Jan 11, 1996

Appl. No.:

08/583761

Inventors:

Robert F. Baugh - Parker CO 80134

International Classification:

C12Q 156

US Classification:

435 13, 436 69

Abstract:

Blood is tested for clot lysis conditions such as natural lytic capabilities, the effect of previously administered thrombolytic and anti-thrombolytic agents, and dose responses thereto, by forming a clot in a sample of blood, lysing the clot, and measuring the elapsed time period from initial clot formation to clot lysis, all while continuously evaluating the blood sample. Thrombolytic agents include streptokinase, urokinase and recombinant tissue plasminogen activator. Plasmin and plasminogen activator inhibitors, clot activating agents (e. g. kaolin), and agents to deactivate anticoagulants (e. g. heparinase) may also be used as reagents during testing.

US Patent:

6541262, Apr 1, 2003

Filed:

Apr 28, 2000

Appl. No.:

09/560470

Inventors:

Robert F. Baugh - Parker CO
Colleen Lutz - Plymouth MN

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

G01N 3386

US Classification:

436 69, 422 73, 600369, 73 6441

Abstract:

A method and device for testing a sample of fresh whole blood. In particular the present invention provides a method and device for testing a sample of fresh whole blood to determine whether a patient would benefit from the administration of a blood factor (such as AT III. ).

US Patent:

6555064, Apr 29, 2003

Filed:

Mar 16, 2001

Appl. No.:

09/811216

Inventors:

Robert F. Baugh - Parker CO
Carole G. Lane - Greenwood Village CO
Adrian C. Wilson - Denver CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

G01N 3386

US Classification:

422 681, 422 73, 436 10, 436 69

Abstract:

An apparatus is provided for performing an activated clotting time test on a sample of blood containing platelets using a plunger sensor technique, the apparatus comprising a test cell, and wherein the test cell comprises an anticoagulant, a contact activator, and a predetermined amount of a platelet inactivating agent.

US Patent:

6555066, Apr 29, 2003

Filed:

Mar 16, 2001

Appl. No.:

09/810747

Inventors:

Robert F. Baugh - Parker CO
Carole G. Lane - Greenwood Village CO
Adrian C. Wilson - Denver CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

G01N 3316

US Classification:

422 73, 436 10, 436 69, 435 4, 435 13

Abstract:

An apparatus for performing a platelet inhibition test on a sample of blood is provided, comprising a plurality of test cells, the cells being adapted for receiving an aliquot portion of the sample, wherein each of the cells comprises an anticoagulant and a clotting activator, and wherein at least one of the cells further comprises a platelet inactivating agent, wherein a clotting time is determined for each of the aliquot portions, and wherein a relative clotting time for each of the aliquot portions comprising the platelet inhibitor is determined as compared to a reference clotting time for a cell containing no platelet inhibitor, wherein the relative clotting times for the cells are determinative of the platelet inhibition of the sample.

US Patent:

6555381, Apr 29, 2003

Filed:

Mar 16, 2001

Appl. No.:

09/810740

Inventors:

Robert F. Baugh - Parker CO
Carole G. Lane - Greenwood Village CO
Adrian C. Wilson - Denver CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

G01N 3386

US Classification:

436 69, 436 10, 422 73, 435 4, 435 13

Abstract:

A method of determining a contact activator for platelet activation and/or clotting activation is provided, comprising placing a predetermined amount of an anticoagulant in each cell of a multicell test cartridge, placing a predetermined amount of a platelet inactivating agent in each cell, and placing a measured amount of contact activator in each cell, the amount of contact activator in each cell differing from the amount in each other cell. An aliquot of a blood sample is added to each cell, and the blood sample aliquot, clotting reagent and platelet inactivating agent are mixed. Each cell sample is allowed to clot, and the clotting time for each cell is measured. The relative clotting times are used to determine the platelet activation and/or clotting activation effect of the clotting activator.

US Patent:

6596180, Jul 22, 2003

Filed:

Apr 9, 2001

Appl. No.:

09/833234

Inventors:

Robert F. Baugh - Parker CO
Lisa M. Lim - Mill Creek WA
Julie S. Johnston - Conifer CO
John G. Rivera - Reading PA
Victor D. Dolecek - Englewood CO

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

B01D 2126

US Classification:

210782, 2101981, 210200, 210295, 2103601, 2103801, 210806, 422 44, 422 72, 424530, 424531, 424532, 436177, 494 21, 494 36, 494 37, 494 43, 494 45

Abstract:

A centrifuge system for the formation of an autologous platelet gel wherein all of the blood components for the gel are derived from a patient to whom the gel is to be applied. First a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma or platelet poor plasma is then automatically drawn out of the centrifuge bag and proportioned into separate chambers in a dispenser. The first portion is activated where a clot is formed and thrombin is obtained. The thrombin is then latter mixed with the second portion to obtain a platelet gel.